Evidence map›Paper›PMID 33346798›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

HIV Prevention Trials Network 078: High Prevalence of Hepatitis C Virus Antibodies Among Urban US Men Who Have Sex With Men, Independent of Human Immunodeficiency Virus Status.

Risha Irvin, Theresa Gamble, Jowanna Malone, Zhe Wang, Ethan Wilson, James P Hughes, Jason Farley, Kenneth H Mayer, Carlos Del Rio, D Scott Batey and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Risha IrvinJohns Hopkins University, Baltimore, Maryland, USA.
Theresa GambleHPTN Leadership and Operations Center, FHI 360, Durham, North Carolina, USA.
Jowanna MaloneJohns Hopkins University, Baltimore, Maryland, USA.
Zhe WangStatistical Center for HIV/AIDS Research and Prevention, Seattle, Washington , USA.
Ethan WilsonStatistical Center for HIV/AIDS Research and Prevention, Seattle, Washington , USA.
James P HughesUniversity of Washington, Seattle, Washington, USA.
Jason FarleyJohns Hopkins University, Baltimore, Maryland, USA.
Kenneth H MayerThe Fenway Institute and Harvard Medical School, Boston, Massachusetts, USA.
Carlos Del RioEmory University School of Medicine, Atlanta, Georgia, USA.
D Scott BateyThe University of Alabama at Birmingham, Birmingham, Alabama, USA.
Vanessa CummingsJohns Hopkins University, Baltimore, Maryland, USA.
Robert H RemienHIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute and Columbia University, New York, New York, USA.
Chris BeyrerJohns Hopkins University, Baltimore, Maryland, USA.
Chloe L ThioJohns Hopkins University, Baltimore, Maryland, USA.
Johns Hopkins University · USCancer Research And Biostatistics · USColumbia University · USEmory University · USFamily Health International 360 · USHarvard University · USUniversity of Alabama at Birmingham · USUniversity of Washington · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV EliminationR01DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI IRVIN, RISHA, THOMAS, DAVID L · 2000 to 2024
$8.7M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069412NIDA NIH HHS R01 DA013806NIDA NIH HHS R37 DA013806
6 · The paper itself

Abstract

backgroundSexual transmission of hepatitis C virus (HCV) is uncommon, yet documented among men who have sex with men (MSM), primarily among those with human immunodeficiency virus (HIV).

methodsIn the HIV Prevention Trials Network 078 study (HPTN 078), which assessed an integrated strategy to achieve HIV viral suppression, 1305 MSM were screened across 4 geographically diverse US cities. At screening, demographic/behavioral/psychosocial questionnaires were completed, along with HIV and HCV testing. Multivariable logistic regression was used to evaluate associations with HCV antibody positivity.

resultsAmong the 1287 (99%) of the MSM with HCV antibody results, the median age was 41, 69% were black, 85% had a high school education or more, 35% were employed, 70% had HIV, and 21% had undergone substance use counseling. The median lifetime number of male sexual partners was 17 (interquartile range, 6-50), and 246 (19%) were HCV antibody positive. HCV antibody positivity was high in MSM with HIV (20%) and MSM without HIV (17%) (P = .12) and was higher in those receiving substance use counseling (36%) than in those who had not (15%) (P ≤ .01). Substance use counseling (odds ratio, 2.51; 95% confidence interval, 1.80-3.51) and unstable housing (2.16; 1.40-3.33) were associated with HCV antibody positivity.

conclusionsNearly 1 in 5 MSM screened for HPTN 078 have been infected with HCV. The prevalence is high regardless of HIV status and is high even in those who did not undergo substance use counseling. In HIV burden networks, high HCV infection prevalence may occur in MSM without HIV. As implementation of preexposure prophylaxis expands and condom use declines, routine HCV counseling and screening among MSM are important.

Indexed as

Hepatitis CHIV InfectionsSexual and Gender MinoritiesAdultHepatitis C AntibodiesHIVHomosexuality, MaleHumansMalePrevalenceHepatitis C Antibodieshepatitis CHIVmen who have sex with men

Identifiers

PMID33346798
PMCPMC8492204
OpenAlexW3113965032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.